ECU
BEAM icon

Eisler Capital (US)’s Beam Therapeutics BEAM Stock Holding History

Eisler Capital (US)’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-34,378
Closed -$805K – 496
2024
Q2 		$805K Buy
+34,378
New +$844K 0.01% 520

Other funds holding BEAM

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Eisler Capital (US)'s BEAM Position: Q3 2024 in Review

Eisler Capital (US) sold out of Beam Therapeutics (BEAM) in Q3 2024, closing a stake of 34,378 shares — an estimated $805K sold.

Eisler Capital (US) first reported a position in BEAM in Q2 2024 and held it in 1 quarter. The position peaked at $805K in Q2 2024. 221 funds tracked by Wall St. Rank hold BEAM as of Q3 2024.

  • Eisler Capital (US) reported no remaining Beam Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Eisler Capital (US) sold 34,378 Beam Therapeutics shares in Q3 2024, an estimated $805K.
  • Eisler Capital (US) first reported a position in Beam Therapeutics in Q2 2024 and held it in 1 quarter.
  • Eisler Capital (US)'s Beam Therapeutics position peaked at $805K in Q2 2024.
  • 221 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2024.

Based on Eisler Capital (US)'s 13F filing for Q3 2024, filed 14 Nov 2024.